National PreP service would be cost effective, research finds

Pharma Times

20 October 2017 - Providing pre-exposure prophylaxis treatment to men who have sex with men at high risk of contracting HIV in England would be cost-effective and could prevent 25 percent of cases of infection, according to UCL research.

PrEP treatment is a combination of two anti-HIV drugs (emtricitabine and tenofovir) taken daily or around sexual activity to reduce a person’s risk of HIV infection.

The approach is currently being trialled by the NHS over an initial three-year period in around 10,000 people, with sexual health clinics in London, Brighton, Manchester, Liverpool and Sheffield amongst the first to start enrolling people in order to assess the full impact of the service.

Read Pharma Times article

Michael Wonder

Posted by:

Michael Wonder